conversations stringlengths 2.08k 188k | source stringclasses 1
value | score float64 0.03 0.87 |
|---|---|---|
[{'from': 'human', 'value': {'Study Title': 'Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers', 'Primary Outcome Measures': 'Physician assessed severity of breathlessness, Breathlessness requiring admission or supplementary oxygen, breathlessness requiring intervention \\< 24 hours, Breathlessness ... | from_dataset | 0.524417 |
[{'from': 'human', 'value': {'Study Title': 'Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers', 'Primary Outcome Measures': 'Physician assessed severity of breathlessness, Breathlessness requiring admission or supplementary oxygen, breathlessness requiring intervention \\< 24 hours, Breathlessness ... | from_dataset | 0.072 |
[{'from': 'human', 'value': {'Study Title': 'Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers', 'Primary Outcome Measures': 'Physician assessed severity of breathlessness, Breathlessness requiring admission or supplementary oxygen, breathlessness requiring intervention \\< 24 hours, Breathlessness ... | from_dataset | 0.069169 |
[{'from': 'human', 'value': {'Study Title': 'Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers', 'Primary Outcome Measures': 'Physician assessed severity of breathlessness, Breathlessness requiring admission or supplementary oxygen, breathlessness requiring intervention \\< 24 hours, Breathlessness ... | from_dataset | 0.067912 |
[{'from': 'human', 'value': {'Study Title': 'Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers', 'Primary Outcome Measures': 'Physician assessed severity of breathlessness, Breathlessness requiring admission or supplementary oxygen, breathlessness requiring intervention \\< 24 hours, Breathlessness ... | from_dataset | 0.064796 |
[{'from': 'human', 'value': {'Study Title': 'Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers', 'Primary Outcome Measures': 'Physician assessed severity of breathlessness, Breathlessness requiring admission or supplementary oxygen, breathlessness requiring intervention \\< 24 hours, Breathlessness ... | from_dataset | 0.06276 |
[{'from': 'human', 'value': {'Study Title': 'Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers', 'Primary Outcome Measures': 'Physician assessed severity of breathlessness, Breathlessness requiring admission or supplementary oxygen, breathlessness requiring intervention \\< 24 hours, Breathlessness ... | from_dataset | 0.061001 |
[{'from': 'human', 'value': {'Study Title': 'Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers', 'Primary Outcome Measures': 'Physician assessed severity of breathlessness, Breathlessness requiring admission or supplementary oxygen, breathlessness requiring intervention \\< 24 hours, Breathlessness ... | from_dataset | 0.060377 |
[{'from': 'human', 'value': {'Study Title': 'Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers', 'Primary Outcome Measures': 'Physician assessed severity of breathlessness, Breathlessness requiring admission or supplementary oxygen, breathlessness requiring intervention \\< 24 hours, Breathlessness ... | from_dataset | 0.056299 |
[{'from': 'human', 'value': {'Study Title': 'Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers', 'Primary Outcome Measures': 'Physician assessed severity of breathlessness, Breathlessness requiring admission or supplementary oxygen, breathlessness requiring intervention \\< 24 hours, Breathlessness ... | from_dataset | 0.056094 |
[{'from': 'human', 'value': '{Study Title: Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis, Primary Outcome Measures: Number of subjects with treatment-emergent adverse events (TEAEs), Safety and tolerability will be assessed by adverse events (AEs), safety lab... | from_dataset | 0.249949 |
[{'from': 'human', 'value': '{Study Title: Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis, Primary Outcome Measures: Number of subjects with treatment-emergent adverse events (TEAEs), Safety and tolerability will be assessed by adverse events (AEs), safety lab... | from_dataset | 0.247159 |
[{'from': 'human', 'value': '{Study Title: Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis, Primary Outcome Measures: Number of subjects with treatment-emergent adverse events (TEAEs), Safety and tolerability will be assessed by adverse events (AEs), safety lab... | from_dataset | 0.235002 |
[{'from': 'human', 'value': '{Study Title: Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis, Primary Outcome Measures: Number of subjects with treatment-emergent adverse events (TEAEs), Safety and tolerability will be assessed by adverse events (AEs), safety lab... | from_dataset | 0.228621 |
[{'from': 'human', 'value': '{Study Title: Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis, Primary Outcome Measures: Number of subjects with treatment-emergent adverse events (TEAEs), Safety and tolerability will be assessed by adverse events (AEs), safety lab... | from_dataset | 0.226267 |
[{'from': 'human', 'value': '{Study Title: Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis, Primary Outcome Measures: Number of subjects with treatment-emergent adverse events (TEAEs), Safety and tolerability will be assessed by adverse events (AEs), safety lab... | from_dataset | 0.22402 |
[{'from': 'human', 'value': '{Study Title: Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis, Primary Outcome Measures: Number of subjects with treatment-emergent adverse events (TEAEs), Safety and tolerability will be assessed by adverse events (AEs), safety lab... | from_dataset | 0.221401 |
[{'from': 'human', 'value': '{Study Title: Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis, Primary Outcome Measures: Number of subjects with treatment-emergent adverse events (TEAEs), Safety and tolerability will be assessed by adverse events (AEs), safety lab... | from_dataset | 0.219434 |
[{'from': 'human', 'value': '{Study Title: Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis, Primary Outcome Measures: Number of subjects with treatment-emergent adverse events (TEAEs), Safety and tolerability will be assessed by adverse events (AEs), safety lab... | from_dataset | 0.217268 |
[{'from': 'human', 'value': '{Study Title: Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis, Primary Outcome Measures: Number of subjects with treatment-emergent adverse events (TEAEs), Safety and tolerability will be assessed by adverse events (AEs), safety lab... | from_dataset | 0.215126 |
[{'from': 'human', 'value': '{Study Title: Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study, Primary Outcome Measures: Target Lesion Failure (TLF), Target Lesion Failure (composite of cardiac death, target vessel MI, and clinically-indicated target lesion revascularization), 6 months|Change i... | from_dataset | 0.61593 |
[{'from': 'human', 'value': '{Study Title: Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study, Primary Outcome Measures: Target Lesion Failure (TLF), Target Lesion Failure (composite of cardiac death, target vessel MI, and clinically-indicated target lesion revascularization), 6 months|Change i... | from_dataset | 0.566452 |
[{'from': 'human', 'value': '{Study Title: Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study, Primary Outcome Measures: Target Lesion Failure (TLF), Target Lesion Failure (composite of cardiac death, target vessel MI, and clinically-indicated target lesion revascularization), 6 months|Change i... | from_dataset | 0.551906 |
[{'from': 'human', 'value': '{Study Title: Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study, Primary Outcome Measures: Target Lesion Failure (TLF), Target Lesion Failure (composite of cardiac death, target vessel MI, and clinically-indicated target lesion revascularization), 6 months|Change i... | from_dataset | 0.52145 |
[{'from': 'human', 'value': '{Study Title: Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study, Primary Outcome Measures: Target Lesion Failure (TLF), Target Lesion Failure (composite of cardiac death, target vessel MI, and clinically-indicated target lesion revascularization), 6 months|Change i... | from_dataset | 0.517918 |
[{'from': 'human', 'value': '{Study Title: Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study, Primary Outcome Measures: Target Lesion Failure (TLF), Target Lesion Failure (composite of cardiac death, target vessel MI, and clinically-indicated target lesion revascularization), 6 months|Change i... | from_dataset | 0.513071 |
[{'from': 'human', 'value': '{Study Title: Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study, Primary Outcome Measures: Target Lesion Failure (TLF), Target Lesion Failure (composite of cardiac death, target vessel MI, and clinically-indicated target lesion revascularization), 6 months|Change i... | from_dataset | 0.446 |
[{'from': 'human', 'value': '{Study Title: Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study, Primary Outcome Measures: Target Lesion Failure (TLF), Target Lesion Failure (composite of cardiac death, target vessel MI, and clinically-indicated target lesion revascularization), 6 months|Change i... | from_dataset | 0.429853 |
[{'from': 'human', 'value': '{Study Title: Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study, Primary Outcome Measures: Target Lesion Failure (TLF), Target Lesion Failure (composite of cardiac death, target vessel MI, and clinically-indicated target lesion revascularization), 6 months|Change i... | from_dataset | 0.366806 |
[{'from': 'human', 'value': '{Study Title: Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study, Primary Outcome Measures: Target Lesion Failure (TLF), Target Lesion Failure (composite of cardiac death, target vessel MI, and clinically-indicated target lesion revascularization), 6 months|Change i... | from_dataset | 0.33937 |
[{'from': 'human', 'value': '{Study Title: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV), Primary Outcome Measures: Complete Response, No emesis and no further rescue medication, 10 min. after infusion start through 24 hrs. or discharge, Secondary Outcome Me... | from_dataset | 0.235088 |
[{'from': 'human', 'value': '{Study Title: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV), Primary Outcome Measures: Complete Response, No emesis and no further rescue medication, 10 min. after infusion start through 24 hrs. or discharge, Secondary Outcome Me... | from_dataset | 0.232637 |
[{'from': 'human', 'value': '{Study Title: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV), Primary Outcome Measures: Complete Response, No emesis and no further rescue medication, 10 min. after infusion start through 24 hrs. or discharge, Secondary Outcome Me... | from_dataset | 0.224891 |
[{'from': 'human', 'value': '{Study Title: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV), Primary Outcome Measures: Complete Response, No emesis and no further rescue medication, 10 min. after infusion start through 24 hrs. or discharge, Secondary Outcome Me... | from_dataset | 0.215968 |
[{'from': 'human', 'value': '{Study Title: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV), Primary Outcome Measures: Complete Response, No emesis and no further rescue medication, 10 min. after infusion start through 24 hrs. or discharge, Secondary Outcome Me... | from_dataset | 0.213406 |
[{'from': 'human', 'value': '{Study Title: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV), Primary Outcome Measures: Complete Response, No emesis and no further rescue medication, 10 min. after infusion start through 24 hrs. or discharge, Secondary Outcome Me... | from_dataset | 0.206725 |
[{'from': 'human', 'value': '{Study Title: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV), Primary Outcome Measures: Complete Response, No emesis and no further rescue medication, 10 min. after infusion start through 24 hrs. or discharge, Secondary Outcome Me... | from_dataset | 0.197435 |
[{'from': 'human', 'value': '{Study Title: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV), Primary Outcome Measures: Complete Response, No emesis and no further rescue medication, 10 min. after infusion start through 24 hrs. or discharge, Secondary Outcome Me... | from_dataset | 0.190749 |
[{'from': 'human', 'value': '{Study Title: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV), Primary Outcome Measures: Complete Response, No emesis and no further rescue medication, 10 min. after infusion start through 24 hrs. or discharge, Secondary Outcome Me... | from_dataset | 0.18849 |
[{'from': 'human', 'value': '{Study Title: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV), Primary Outcome Measures: Complete Response, No emesis and no further rescue medication, 10 min. after infusion start through 24 hrs. or discharge, Secondary Outcome Me... | from_dataset | 0.186547 |
[{'from': 'human', 'value': {'Study Title': 'A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients', 'Primary Outcome Measures': 'The incidence and severity of treatment-related, adverse events as ass... | from_dataset | 0.264788 |
[{'from': 'human', 'value': {'Study Title': 'A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients', 'Primary Outcome Measures': 'The incidence and severity of treatment-related, adverse events as ass... | from_dataset | 0.235915 |
[{'from': 'human', 'value': {'Study Title': 'A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients', 'Primary Outcome Measures': 'The incidence and severity of treatment-related, adverse events as ass... | from_dataset | 0.232529 |
[{'from': 'human', 'value': {'Study Title': 'A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients', 'Primary Outcome Measures': 'The incidence and severity of treatment-related, adverse events as ass... | from_dataset | 0.21821 |
[{'from': 'human', 'value': {'Study Title': 'A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients', 'Primary Outcome Measures': 'The incidence and severity of treatment-related, adverse events as ass... | from_dataset | 0.218196 |
[{'from': 'human', 'value': {'Study Title': 'A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients', 'Primary Outcome Measures': 'The incidence and severity of treatment-related, adverse events as ass... | from_dataset | 0.218057 |
[{'from': 'human', 'value': {'Study Title': 'A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients', 'Primary Outcome Measures': 'The incidence and severity of treatment-related, adverse events as ass... | from_dataset | 0.211326 |
[{'from': 'human', 'value': {'Study Title': 'A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients', 'Primary Outcome Measures': 'The incidence and severity of treatment-related, adverse events as ass... | from_dataset | 0.210928 |
[{'from': 'human', 'value': {'Study Title': 'A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients', 'Primary Outcome Measures': 'The incidence and severity of treatment-related, adverse events as ass... | from_dataset | 0.20746 |
[{'from': 'human', 'value': {'Study Title': 'A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients', 'Primary Outcome Measures': 'The incidence and severity of treatment-related, adverse events as ass... | from_dataset | 0.204842 |
[{'from': 'human', 'value': {'Study Title': 'A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers', 'Primary Outcome Measures': 'Cmax, Maximum concentration of drug in plasma of Fimasartan, Linagliptin, Fimasartan: 0-48 hours after administration,... | from_dataset | 0.246447 |
[{'from': 'human', 'value': {'Study Title': 'A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers', 'Primary Outcome Measures': 'Cmax, Maximum concentration of drug in plasma of Fimasartan, Linagliptin, Fimasartan: 0-48 hours after administration,... | from_dataset | 0.23853 |
[{'from': 'human', 'value': {'Study Title': 'A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers', 'Primary Outcome Measures': 'Cmax, Maximum concentration of drug in plasma of Fimasartan, Linagliptin, Fimasartan: 0-48 hours after administration,... | from_dataset | 0.21849 |
[{'from': 'human', 'value': {'Study Title': 'A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers', 'Primary Outcome Measures': 'Cmax, Maximum concentration of drug in plasma of Fimasartan, Linagliptin, Fimasartan: 0-48 hours after administration,... | from_dataset | 0.210392 |
[{'from': 'human', 'value': {'Study Title': 'A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers', 'Primary Outcome Measures': 'Cmax, Maximum concentration of drug in plasma of Fimasartan, Linagliptin, Fimasartan: 0-48 hours after administration,... | from_dataset | 0.205411 |
[{'from': 'human', 'value': {'Study Title': 'A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers', 'Primary Outcome Measures': 'Cmax, Maximum concentration of drug in plasma of Fimasartan, Linagliptin, Fimasartan: 0-48 hours after administration,... | from_dataset | 0.204801 |
[{'from': 'human', 'value': {'Study Title': 'A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers', 'Primary Outcome Measures': 'Cmax, Maximum concentration of drug in plasma of Fimasartan, Linagliptin, Fimasartan: 0-48 hours after administration,... | from_dataset | 0.19504 |
[{'from': 'human', 'value': {'Study Title': 'A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers', 'Primary Outcome Measures': 'Cmax, Maximum concentration of drug in plasma of Fimasartan, Linagliptin, Fimasartan: 0-48 hours after administration,... | from_dataset | 0.193425 |
[{'from': 'human', 'value': {'Study Title': 'A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers', 'Primary Outcome Measures': 'Cmax, Maximum concentration of drug in plasma of Fimasartan, Linagliptin, Fimasartan: 0-48 hours after administration,... | from_dataset | 0.185671 |
[{'from': 'human', 'value': {'Study Title': 'A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers', 'Primary Outcome Measures': 'Cmax, Maximum concentration of drug in plasma of Fimasartan, Linagliptin, Fimasartan: 0-48 hours after administration,... | from_dataset | 0.184139 |
[{'from': 'human', 'value': {'Study Title': 'Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure', 'Primary Outcome Measures': 'Postoperative visit procedures will include visual acuity and quality assessments and monitoring for surgical complications necessitating retreatment., 1 year', 'Secondar... | from_dataset | 0.320933 |
[{'from': 'human', 'value': {'Study Title': 'Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure', 'Primary Outcome Measures': 'Postoperative visit procedures will include visual acuity and quality assessments and monitoring for surgical complications necessitating retreatment., 1 year', 'Secondar... | from_dataset | 0.250587 |
[{'from': 'human', 'value': {'Study Title': 'Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure', 'Primary Outcome Measures': 'Postoperative visit procedures will include visual acuity and quality assessments and monitoring for surgical complications necessitating retreatment., 1 year', 'Secondar... | from_dataset | 0.210157 |
[{'from': 'human', 'value': {'Study Title': 'Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure', 'Primary Outcome Measures': 'Postoperative visit procedures will include visual acuity and quality assessments and monitoring for surgical complications necessitating retreatment., 1 year', 'Secondar... | from_dataset | 0.209284 |
[{'from': 'human', 'value': {'Study Title': 'Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure', 'Primary Outcome Measures': 'Postoperative visit procedures will include visual acuity and quality assessments and monitoring for surgical complications necessitating retreatment., 1 year', 'Secondar... | from_dataset | 0.20589 |
[{'from': 'human', 'value': {'Study Title': 'Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure', 'Primary Outcome Measures': 'Postoperative visit procedures will include visual acuity and quality assessments and monitoring for surgical complications necessitating retreatment., 1 year', 'Secondar... | from_dataset | 0.200654 |
[{'from': 'human', 'value': {'Study Title': 'Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure', 'Primary Outcome Measures': 'Postoperative visit procedures will include visual acuity and quality assessments and monitoring for surgical complications necessitating retreatment., 1 year', 'Secondar... | from_dataset | 0.194431 |
[{'from': 'human', 'value': {'Study Title': 'Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure', 'Primary Outcome Measures': 'Postoperative visit procedures will include visual acuity and quality assessments and monitoring for surgical complications necessitating retreatment., 1 year', 'Secondar... | from_dataset | 0.185734 |
[{'from': 'human', 'value': {'Study Title': 'Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure', 'Primary Outcome Measures': 'Postoperative visit procedures will include visual acuity and quality assessments and monitoring for surgical complications necessitating retreatment., 1 year', 'Secondar... | from_dataset | 0.185179 |
[{'from': 'human', 'value': {'Study Title': 'Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure', 'Primary Outcome Measures': 'Postoperative visit procedures will include visual acuity and quality assessments and monitoring for surgical complications necessitating retreatment., 1 year', 'Secondar... | from_dataset | 0.18356 |
[{'from': 'human', 'value': '{Study Title: Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers, Primary Outcome Measures: Number of participants with adverse events, Up to 16 days after drug administration|Number of participants with clinically significant changes in vital signs, U... | from_dataset | 0.664916 |
[{'from': 'human', 'value': '{Study Title: Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers, Primary Outcome Measures: Number of participants with adverse events, Up to 16 days after drug administration|Number of participants with clinically significant changes in vital signs, U... | from_dataset | 0.617235 |
[{'from': 'human', 'value': '{Study Title: Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers, Primary Outcome Measures: Number of participants with adverse events, Up to 16 days after drug administration|Number of participants with clinically significant changes in vital signs, U... | from_dataset | 0.608834 |
[{'from': 'human', 'value': '{Study Title: Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers, Primary Outcome Measures: Number of participants with adverse events, Up to 16 days after drug administration|Number of participants with clinically significant changes in vital signs, U... | from_dataset | 0.382441 |
[{'from': 'human', 'value': '{Study Title: Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers, Primary Outcome Measures: Number of participants with adverse events, Up to 16 days after drug administration|Number of participants with clinically significant changes in vital signs, U... | from_dataset | 0.365618 |
[{'from': 'human', 'value': '{Study Title: Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers, Primary Outcome Measures: Number of participants with adverse events, Up to 16 days after drug administration|Number of participants with clinically significant changes in vital signs, U... | from_dataset | 0.360654 |
[{'from': 'human', 'value': '{Study Title: Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers, Primary Outcome Measures: Number of participants with adverse events, Up to 16 days after drug administration|Number of participants with clinically significant changes in vital signs, U... | from_dataset | 0.302495 |
[{'from': 'human', 'value': '{Study Title: Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers, Primary Outcome Measures: Number of participants with adverse events, Up to 16 days after drug administration|Number of participants with clinically significant changes in vital signs, U... | from_dataset | 0.290329 |
[{'from': 'human', 'value': '{Study Title: Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers, Primary Outcome Measures: Number of participants with adverse events, Up to 16 days after drug administration|Number of participants with clinically significant changes in vital signs, U... | from_dataset | 0.280242 |
[{'from': 'human', 'value': '{Study Title: Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers, Primary Outcome Measures: Number of participants with adverse events, Up to 16 days after drug administration|Number of participants with clinically significant changes in vital signs, U... | from_dataset | 0.278946 |
[{'from': 'human', 'value': '{Study Title: Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis, Primary Outcome Measures: The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) < 2.6., Effects of the combination of etanercept ... | from_dataset | 0.275714 |
[{'from': 'human', 'value': '{Study Title: Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis, Primary Outcome Measures: The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) < 2.6., Effects of the combination of etanercept ... | from_dataset | 0.255172 |
[{'from': 'human', 'value': '{Study Title: Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis, Primary Outcome Measures: The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) < 2.6., Effects of the combination of etanercept ... | from_dataset | 0.245015 |
[{'from': 'human', 'value': '{Study Title: Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis, Primary Outcome Measures: The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) < 2.6., Effects of the combination of etanercept ... | from_dataset | 0.208376 |
[{'from': 'human', 'value': '{Study Title: Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis, Primary Outcome Measures: The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) < 2.6., Effects of the combination of etanercept ... | from_dataset | 0.18471 |
[{'from': 'human', 'value': '{Study Title: Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis, Primary Outcome Measures: The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) < 2.6., Effects of the combination of etanercept ... | from_dataset | 0.173717 |
[{'from': 'human', 'value': '{Study Title: Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis, Primary Outcome Measures: The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) < 2.6., Effects of the combination of etanercept ... | from_dataset | 0.142114 |
[{'from': 'human', 'value': '{Study Title: Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis, Primary Outcome Measures: The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) < 2.6., Effects of the combination of etanercept ... | from_dataset | 0.141722 |
[{'from': 'human', 'value': '{Study Title: Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis, Primary Outcome Measures: The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) < 2.6., Effects of the combination of etanercept ... | from_dataset | 0.137544 |
[{'from': 'human', 'value': '{Study Title: Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis, Primary Outcome Measures: The Number of Participants Achieving Remission As Measured by a Disease Activity Score for 28 Joints (DAS 28) < 2.6., Effects of the combination of etanercept ... | from_dataset | 0.133246 |
[{'from': 'human', 'value': '{Study Title: VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram, Primary Outcome Measures: To investigate the effect at steady-state of TVR 750 mg q8h on the steady-state pharmacokinetics of escitalopram 10 mg q.d. in healthy participants... | from_dataset | 0.242553 |
[{'from': 'human', 'value': '{Study Title: VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram, Primary Outcome Measures: To investigate the effect at steady-state of TVR 750 mg q8h on the steady-state pharmacokinetics of escitalopram 10 mg q.d. in healthy participants... | from_dataset | 0.202751 |
[{'from': 'human', 'value': '{Study Title: VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram, Primary Outcome Measures: To investigate the effect at steady-state of TVR 750 mg q8h on the steady-state pharmacokinetics of escitalopram 10 mg q.d. in healthy participants... | from_dataset | 0.197642 |
[{'from': 'human', 'value': '{Study Title: VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram, Primary Outcome Measures: To investigate the effect at steady-state of TVR 750 mg q8h on the steady-state pharmacokinetics of escitalopram 10 mg q.d. in healthy participants... | from_dataset | 0.196682 |
[{'from': 'human', 'value': '{Study Title: VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram, Primary Outcome Measures: To investigate the effect at steady-state of TVR 750 mg q8h on the steady-state pharmacokinetics of escitalopram 10 mg q.d. in healthy participants... | from_dataset | 0.196347 |
[{'from': 'human', 'value': '{Study Title: VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram, Primary Outcome Measures: To investigate the effect at steady-state of TVR 750 mg q8h on the steady-state pharmacokinetics of escitalopram 10 mg q.d. in healthy participants... | from_dataset | 0.195997 |
[{'from': 'human', 'value': '{Study Title: VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram, Primary Outcome Measures: To investigate the effect at steady-state of TVR 750 mg q8h on the steady-state pharmacokinetics of escitalopram 10 mg q.d. in healthy participants... | from_dataset | 0.19294 |
[{'from': 'human', 'value': '{Study Title: VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram, Primary Outcome Measures: To investigate the effect at steady-state of TVR 750 mg q8h on the steady-state pharmacokinetics of escitalopram 10 mg q.d. in healthy participants... | from_dataset | 0.191326 |
[{'from': 'human', 'value': '{Study Title: VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram, Primary Outcome Measures: To investigate the effect at steady-state of TVR 750 mg q8h on the steady-state pharmacokinetics of escitalopram 10 mg q.d. in healthy participants... | from_dataset | 0.188945 |
[{'from': 'human', 'value': '{Study Title: VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram, Primary Outcome Measures: To investigate the effect at steady-state of TVR 750 mg q8h on the steady-state pharmacokinetics of escitalopram 10 mg q.d. in healthy participants... | from_dataset | 0.188817 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.